No paralogue variants have been mapped to residue 177 for RYR1.
RYR1 | WTMHPASKQRSEGEKVRVGDDIILVSVSSE>R<YLHLSTASGELQVDASFMQTLWNMNPICSR | 207 |
RYR2 | WTIHPASKQRSEGEKVRVGDDLILVSVSSE>R<YLHLSYGNGSLHVDAAFQQTLWSVAPISSG | 220 |
RYR3 | WTIHPASKQRSEGEKVRIGDDLILVSVSSE>R<YLHLSVSNGNIQVDASFMQTLWNVHPTCSG | 210 |
cons | > < |
Protein | CDS | Disease Classification | Disease | dbSNP links | Effect Prediction |
---|---|---|---|---|---|
p.R177C | c.529C>T | Other Myopathy | rs193922757 | SIFT: Polyphen: | |
Reports | Other Myopathy | Correlations between genotype and pharmacological, histological, functional, and clinical phenotypes in malignant hyperthermia susceptibility. Hum Mutat. 2005 26(5):413-25. 16163667 | |||
Other Myopathy | Crystal structure of type I ryanodine receptor amino-terminal beta-trefoil domain reveals a disease-associated mutation "hot spot" loop. Proc Natl Acad Sci U S A. 2009 106(27):11040-4. doi: 10.1073/pnas.0905186106. 19541610 | ||||
Other Myopathy | Genetic variation in RYR1 and malignant hyperthermia phenotypes. Br J Anaesth. 2009 103(4):538-48. doi: 10.1093/bja/aep204. 19648156 | ||||
p.R177H | c.530G>A | Putative Benign | SIFT: Polyphen: |